HV01
Glioblastoma
Pre-clinicalActive
Key Facts
About Mesenkia Therapeutics
Mesenkia Therapeutics is a Swedish pre-clinical biotech company developing first-in-class, single-domain antibody (VHH) therapeutics targeting glioblastoma. Its core technology is based on a novel HVEM antagonistic antibody platform, originating from decades of foundational research by its renowned scientific founders. The company is advancing its lead asset, HV01, towards clinical development, supported by strong academic ties, recent patent allowances, and investment from Almi Invest. Mesenkia aims to address the high unmet clinical need in brain cancer by increasing treatment efficacy and patient quality of life.
View full company profileTherapeutic Areas
Other Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Ropidoxuridine (IPdR) | Shuttle Pharmaceuticals | Phase 2 |
| LNTH-2505 | Lantheus Medical Imaging | Preclinical |
| Leronlimab | CytoDyn | Preclinical |
| Glioblastoma Moonshot | Owkin | Research |
| OPC-001 (PDC Candidate) | Oncopeptides | Phase 1/Window-of-Opportunity |
| αvβ3-targeted ADC | Xintela | Preclinical |
| Undisclosed | Biossil | Phase 2/3 |
| GLIX1 | Hemispherian | Phase 1 |
| InC01 | InCephalo Therapeutics | Pre-clinical |
| Glioblastoma Combination Therapy | JLP Health | Pre-clinical |
| ENV105 | Kairos Pharma | IND Cleared |
| LMP744 | Gibson Oncology | Phase 2 |